$KDS #Kiadis Pharma KIADIS : NK cells as the next frontier in cellular immunotherapy: Since facing disappointment with T cell product ATIR101, Kiadis has rapidly repositioned itself to the NK cell therapy field through the acquisition of… https://t.co/YG8NNGdIS4 #equity #stocks https://t.co/dHdS2sCoYK